0001165527-11-001254.txt : 20111230 0001165527-11-001254.hdr.sgml : 20111230 20111230110934 ACCESSION NUMBER: 0001165527-11-001254 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111222 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20111230 DATE AS OF CHANGE: 20111230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHINA PHARMA HOLDINGS, INC. CENTRAL INDEX KEY: 0001106644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 731564807 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34471 FILM NUMBER: 111288259 BUSINESS ADDRESS: STREET 1: 2ND FLOOR, NO. 17, JINPAN ROAD STREET 2: HAIKOU CITY: HAINAN PROVINCE STATE: F4 ZIP: 570216 BUSINESS PHONE: 8689866811730 MAIL ADDRESS: STREET 1: 2ND FLOOR, NO. 17, JINPAN ROAD STREET 2: HAIKOU CITY: HAINAN PROVINCE STATE: F4 ZIP: 570216 FORMER COMPANY: FORMER CONFORMED NAME: TS ELECTRONICS INC DATE OF NAME CHANGE: 20030818 FORMER COMPANY: FORMER CONFORMED NAME: SOFTSTONE INC DATE OF NAME CHANGE: 20030128 FORMER COMPANY: FORMER CONFORMED NAME: SOFTSTONE INC /DE/ DATE OF NAME CHANGE: 20010808 8-K 1 g5686.htm g5686.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2011


 
    CHINA PHARMA HOLDINGS, INC.    
    (Exact name of Registrant as specified in charter)    
 
 
Delaware
  
001-34471
  
73-1564807
(State or other jurisdiction Incorporation)
  
(Commission File No.)
  
(IRS Employer of Identification No.)
         
Second Floor, No. 17, Jinpan Road
        
Haikou, Hainan Province, China
      
570216
(Address of principal executive offices)
      
(Zip Code)
         
 
Registrant's telephone number, including area code:  +86 898-6681-1730 (China)  
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

[ ] Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange   Act   (17CFR240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

 
 
 

Item 5.07. Submission of Matters to a Vote of Security Holders

On December 22, 2011, China Pharma Holdings, Inc. (the “Company”) held its 2011 annual shareholders meeting (the “Meeting”).  At the Meeting, the only proposal submitted to a vote of the shareholders of the Company was the election of three persons to the Board of Directors of the Company as independent directors.  Holders of 30,592,290 shares of the Company’s common stock were present in person or by proxy at the Meeting, representing 70.27% of the total outstanding shares of common stock and therefore constituting a quorum of more than one-third of the shares outstanding and entitled to vote at the Meeting as of the record date.

Pursuant to shareholder vote, Messrs. Yingwen Zhang, Baowen Dong and Gene Michael Bennett were elected to serve as independent directors until the next annual shareholders meeting or until their successors are duly elected or appointed. The results were as follows:

Director Nominee
  
For
  
Against
  
Withheld
  
Broker Non-Votes
                 
Yingwen Zhang
  
28,399,456
  
0
  
2,192,834
  
n/a
Baowen Dong
  
28,397,586
  
0
  
2,194,704
  
n/a
Gene Michael Bennett
  
24,933,743
  
0
  
5,658,547
  
n/a

 

 
 
2
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: December 23, 2011
 
   
CHINA PHARMA HOLDINGS, INC.
     
     
 
By: 
/s/ Zhilin Li
   
 
Zhilin Li,
   
President and Chief Executive Officer
 

 

 
3